Zydus Lifesciences Q1 Results FY2023, PAT at Rs. 5183 million
On 10th August 2022, Zydus Lifesciences announced its quarterly results for the first quarter of FY2023.
Q1FY23 Key Highlights:
- Revenue from operations at Rs. 40,727 million, up 2% over last year.
- Research & Development (R&D) investments for the quarter stood at Rs. 2,842 million (7.0% of revenues).
- Reported EBITDA for the quarter was Rs. 8,330 million, down 14% YoY. EBITDA margin for the quarter stood at 20.5%.
- Reported Net Profit for the quarter was Rs. 5,183 million, down 12% YoY. Adjusted for exceptional items and loss from discontinued operations, Net Profit for the quarter was Rs. 5,295 million, down 11% YoY.
Business Highlights:
INDIA:
- Registered revenues of Rs. 18,167 million, down 6% YoY. Excluding sales of COVID related products, the business grew 12% YoY
- Formulations business registered revenues of Rs. 11,251 million, down 17% YoY. Excluding sales of COVID related products, generics portfolio and divested products, the branded prescription business grew 9% YoY. The business accounted for 29% of consolidated revenues.
- Consumer Wellness business registered revenues of Rs. 6,916 million, up 18 % YoY. The business accounted for 17% of consolidated revenues.
US FORMULATION BUSINESS:
- Registered revenues of Rs. 15,592 million, up 9% YoY and 10% QoQ. The business accounted for 40% of consolidated revenues.
- In constant currency terms, the business registered revenues of US$ 202 million.
- Filed 8 ANDAs and received approval for 7 new products (including 1 tentative approval) during the quarter.
EMERGING MARKETS FORMULATION BUSINESS:
- The business sustained growth momentum and registered revenues of Rs. 3,155 million, up 14% YoY. The business accounted for 8% of consolidated revenues.
- Growth during the quarter was broad based across most of the geographies.
EUROPE FORMULATION BUSINESS:
- Registered revenues of Rs. 614 million, up 3% YoY. The business accounted for 2% of consolidated revenues.
API BUSINESS:
- Registered revenues of Rs. 1,224 million, down 10% YoY. The business accounted for 3% of consolidated revenues.
Share Market Today
| Indices Name | Price | Price Change (% change) |
|---|---|---|
| S&P ASX 200 | 7555.70 | -82.4 (-1.08%) |
| CAC 40 | 8022.41 | -0.85 (-0.01%) |
| DAX | 17737.36 | -100.04 (-0.56%) |
| Dow Jones | 37986.40 | 211.02 (0.56%) |
| FTSE 100 | 7895.22 | 12.39 (0.16%) |
| Hang Seng | 16224.15 | -161.73 (-0.99%) |
| US Tech Composite | 15287.01 | -319.49 (-2.05%) |
| Nikkei 225 | 37068.28 | -1011.35 (-2.66%) |
| S&P 500 | 4967.23 | -43.89 (-0.88%) |
| Gift Nifty | 22203.50 | 188.5 (0.86%) |
| Shanghai Composite | 3065.26 | -8.96 (-0.29%) |
| Taiwan Weighted | 19527.12 | -774.08 (-3.81%) |
| US 30 | 37973.70 | 209.7 (0.56%) |
Start Investing in 5 mins*
Rs. 20 Flat Per Order | 0% Brokerage
